Phortress & PMX 610 Bibliographies

DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Trapani V, Patel V, Leong C-O, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MFG, Sausville EA and Loaiza-Perez AI. Brit J Can., 2003, 88, 599-605.

Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Monks A, Harris E, Hose C, Connelly J, Sausville A. Mol Pharmacol., 2003, 6, 766-772.

Induction of CYP1A1 in tumor cells by the antitumor agent 2-(4-amino-3-methyl)-5-fluorobenzothiazole: a potential surrogate marker for patient sensitivity. Hose C, Hollingshead M, Sausville EA, Monks A. Mol. Can. Therapeutics, 2003, 2, 1265-1272.

Antitumor Benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl) benzothiazoles to reactive intermediates by cytochrome P450 1A1. O`Brien S, Browne HL, Bradshaw TD, Westwell AD, Laughton CA, Stevens MFG. Org. Biomol. Chem.,2003, 1, 493-497.

Antitumour benzothiazoles. Part 20: 3`-cyano and 3`alkynyl- substituted 2-(4-aminophenyl)benzothiazoles as new potent and selective analogues. Hutchinson I, Bradshaw TD, Matthews CS, Stevens MFG and Westwell AD. Bioorg. and Med. Chem. Lett., 2003, 13, 471-474.

The aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent 2-(4-aminophenyl)benzothiazole. Loaiza-Perez A, Trapani, V, Hose C, Singh SS, Trepel J, Stevens MFG, Bradshaw TD and Sausville EA. Molecular Pharmacol., 2002, 61, 13-19.

Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles Bradshaw TD, Fichtner I, Bibby MJ, Double JA, Cooper PA, Alley MC, Tomaszewjski, JE, Donahue S, Stinson SF, Sausville EA and Stevens MFG. Molecular Cancer Therapeutics, 2002, 1, 239-246.

In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Bradshaw TD, Chua M-S, Browne HL, Trapani V, Sausville EA, Stevens MFG. Brit. J. Cancer, 2002, 86, 1348-1354.

The aryhydrocarbon receptor in anticancer drug design: friend or foe? Bradshaw TD, Trapani V, Vasselin DA, Westwell AD. Current Pharm. Des., 2002, 8, 2475-2490

Antitumor Benzothiazoles. 16. Synthesis and Pharmaceutical Properties of Antitumor 2-(4-Aminophenyl)benzothiazole Amino Acid Prodrugs. Hutchinson I, Jennings SA, Vishnuvajjala BR, Westwell AD and Stevens MFG. J. Med. Chem., 2002, 45, 744-747.